<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A8D6A87B-48C3-49DC-8D55-AA7203607683"><gtr:id>A8D6A87B-48C3-49DC-8D55-AA7203607683</gtr:id><gtr:name>University of British Columbia (UBC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5FA451D-4FA7-423E-93F8-046141371F35"><gtr:id>D5FA451D-4FA7-423E-93F8-046141371F35</gtr:id><gtr:name>University of Western Australia</gtr:name><gtr:address><gtr:line1>35 Stirling Highway</gtr:line1><gtr:line4>Crawley</gtr:line4><gtr:line5>WA 6009</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Medicine</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A8D6A87B-48C3-49DC-8D55-AA7203607683"><gtr:id>A8D6A87B-48C3-49DC-8D55-AA7203607683</gtr:id><gtr:name>University of British Columbia (UBC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5FA451D-4FA7-423E-93F8-046141371F35"><gtr:id>D5FA451D-4FA7-423E-93F8-046141371F35</gtr:id><gtr:name>University of Western Australia</gtr:name><gtr:address><gtr:line1>35 Stirling Highway</gtr:line1><gtr:line4>Crawley</gtr:line4><gtr:line5>WA 6009</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/AAB94755-0482-44D0-86B2-C6EFDB5C36C7"><gtr:id>AAB94755-0482-44D0-86B2-C6EFDB5C36C7</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Abraham</gtr:surname><gtr:orcidId>0000-0001-8952-6057</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/CC1EBF2B-402A-4E06-8FA9-8934D540BF49"><gtr:id>CC1EBF2B-402A-4E06-8FA9-8934D540BF49</gtr:id><gtr:firstName>Robin</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>McAnulty</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1000440"><gtr:id>F1A236BB-F559-41F6-BB3F-88EA0007154E</gtr:id><gtr:title>Epigenetic regulation of cyclooxygenase-2 expression in systemic sclerosis lung fibroblasts</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1000440</gtr:grantReference><gtr:abstractText>Systemic sclerosis (SSc) is a chronic multi-system disease that has a significant effect on quality of life and leads to premature death. Uncontrolled scarring, termed fibrosis, is one of the major characteristic features of this disease and occurs in the lungs in up to 80% of individuals with SSc. Although treatment for some manifestations of SSc has improved, there is no effective therapy for lung fibrosis, other than transplantation, and lung disease is the major cause of death in SSc. Further studies are therefore needed to understand the mechanisms involved in the development and progression of lung fibrosis in SSc in order to identify and develop new effective therapies.

We have previously shown that lack of an enzyme called cyclooxygenase-2 (COX-2), plays important roles in the development of lung fibrosis associated with SSc. Recently we have found that this deficiency in COX-2 can be overcome by treating cells with drugs, called methyltransferase inhibitors and that this restores normal functions to the cells. These drugs block the chemical modification (methylation) of portions of DNA (genes) and some proteins in the cell nucleus, called histones, that can prevent production of proteins and enzymes like COX-2. Using a unique resource of cells obtained from the lungs of individuals with SSc, we aim to identify the mechanisms by which these methyltransferase inhibitors restore COX-2 production and normal cell function. Specifically we will determine whether this occurs through methylation of DNA or proteins and which genes or proteins are involved.

The discovery that COX-2 production and function in cells, obtained from the lungs of patients with SSc, can be restored by methyltransferase inhibitors is of particular importance since drugs of this type are currently in use for the treatment of some cancers. Therefore greater understanding of the mechanisms involved would provide a strong basis for the use of these drugs in clinical trials for the treatment of SSc.</gtr:abstractText><gtr:technicalSummary>Pulmonary fibrosis is a common manifestation of systemic sclerosis (SSc) that is associated with significant morbidity and mortality. Compelling evidence from our group and others demonstrates that failure to up-regulate cyclooxygenase-2 (COX-2) expression plays important roles in the pathogenesis of SSc and other lung fibroses. Our recent data demonstrates that methyltransferase inhibitors restore the responsiveness of SSc lung fibroblasts to inducers of COX-2, and normalisation of cell functions including prostaglandin E2 production and sensitivity to apoptosis. However, this does not associate with changes in COX-2 CpG methylation suggesting an indirect mechanism of methyltransferase inhibition. Additional preliminary data shows increased levels of DNA methyltransferases 1, 3a and 3b in SSc lung and DNA methyltransferase activity in SSc lung fibroblasts compared with controls, as well as, increased repressive methylhistone marks, including histone H3K9me2, both of which could be affected by methyltransferase inhibition. This indicates that DNA and/or histone methylation may play roles in limiting COX-2 expression. 

We therefore aim to determine the mechanism/s by which methyltransferase inhibitors restore SSc lung fibroblast expression of COX-2 and cell function. More specifically, we will: (i) determine whether repressive histone methylation marks are associated with the limited capacity of SSc lung fibroblasts to express COX-2. Repressive methylhistone marks will be systematically investigated and those that are increased in SSc compared with controls and reduced by methyltransferase inhibitors will be assessed by ChIP-quantitative RT-PCR to determine their association with COX-2 expression; (ii) Identify and investigate the role of novel methylated genes in the regulation of fibroblast COX-2 expression. Genes that are hypermethylated in SSc lung fibroblasts and in which methylation is reduced by methyltransferase inhibitors will be identified using methylation arrays followed by characterisation of their ability to regulate COX-2 expression; (iii) elucidate changes in miRNA expression in SSc lung fibroblasts and investigate their role in the deregulation of COX-2 expression. Using expression arrays, miRNAs that exhibit low expression in SSc lung fibroblasts compared with controls and which increase following treatment with methyltransferase inhibitors will be identified and their role in regulating COX-2 expression determined using expression plasmids and siRNA.

Such studies will provide fundamental information on the regulation of cyclooxygenase-2 expression in SSc and, if successful, provide a strong rationale for clinical trials of methyltransferase inhibitors, currently used in other clinical conditions, in SSc. In addition, the methylation and miRNA profiling studies will likely identify novel targets for the investigation and potential treatment of SSc.</gtr:technicalSummary><gtr:fund><gtr:end>2013-04-21</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>283621</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Section of Molecular and Cellular Immunology</gtr:department><gtr:description>Gene transfer</gtr:description><gtr:id>1A31E1A8-8EE9-4877-91F7-1AE54CD4BC06</gtr:id><gtr:impact>Multidisciplinary involving chemists, molecular biologists, cell biologists, pathobiologists and radiologists.
PMID: 22046351
PMID: 23614789
PMID: 23636244</gtr:impact><gtr:outcomeId>DutxEf7DyT1-1</gtr:outcomeId><gtr:partnerContribution>Generation and optimisation of gene delivery vectors for various organs and applications.</gtr:partnerContribution><gtr:piContribution>Expertise in experimental biology and pathology, practical and conceptual.
PMID: 22046351
PMID: 23614789
PMID: 23636244</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Western Australia</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>Centre for Asthma, Allergy and Respiratory Research</gtr:department><gtr:description>Epigenetic regulation of fibroblast function</gtr:description><gtr:id>1AC42F89-1822-40FD-9EBD-9054E03ACF8A</gtr:id><gtr:impact>Sharing and combination of the groups resources and data related to specific gene targets thus enhancing sample size and data integrity.
PMID: 22684844</gtr:impact><gtr:outcomeId>nShJeeGxzVJ-1</gtr:outcomeId><gtr:partnerContribution>Sharing of cells, DNA, RNA and data for the characterisation of specific targets involved in the epigenetic regulation of fibrosis</gtr:partnerContribution><gtr:piContribution>Sharing of Cell lines, DNA, RNA and data for the follow-up and characterisation of specific epigenetic targets related to fibrosis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Fibrosis DPU</gtr:department><gtr:description>Pathogenesis of pulmonary fibrosis</gtr:description><gtr:id>4138945A-F392-430E-806D-2685D06EB9D6</gtr:id><gtr:impact>Generation of data and bioinformatic analysis.</gtr:impact><gtr:outcomeId>Jp4rab6yL6J-1</gtr:outcomeId><gtr:partnerContribution>Technology, analysis of samples and data</gtr:partnerContribution><gtr:piContribution>Sharing of biological samples and knowledge.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of British Columbia</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:department>Department of Anesthesiology, Pharmacology &amp; Therapeutics</gtr:department><gtr:description>Role and regulation of fibroblast function in pulmonary fibrosis</gtr:description><gtr:id>EA0B76A0-DF1B-41A3-B33C-C11E2C56D1EB</gtr:id><gtr:impact>PMID: 22322297</gtr:impact><gtr:outcomeId>bAhyLiZ1Gbm-1</gtr:outcomeId><gtr:partnerContribution>Generation of data and sharing of knowledge.</gtr:partnerContribution><gtr:piContribution>Sharing of cells and knowledge.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Breathing Matters Charity</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B32CF272-0123-4C68-88D1-58DDFCBB1599</gtr:id><gtr:impact>Attended the launch event of the Breathing Matters charity attended by more than 120 patients with respiratory diseases and included discussions with patients on our current research into understanding the disease process.

This has provided a forum for interaction between patients groups at UCLH with similar diseases and with the researchers undertaking research that many of them are participating in.</gtr:impact><gtr:outcomeId>LuY7KF9rbw8</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pharmaceutical Industry</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>62FCB3B2-02C4-4C2C-A3B3-80D332B03B47</gtr:id><gtr:impact>Approximately 40 people attended a two day meeting for the identification of potential therapeutic targets in fibrosis.

Funding of collaborative studies.</gtr:impact><gtr:outcomeId>MfLbGMp33fp</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2011,2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>794596</gtr:amountPounds><gtr:country>Australia, Commonwealth of</gtr:country><gtr:currCode>AUD</gtr:currCode><gtr:currCountryCode>Australia</gtr:currCountryCode><gtr:currLang>en_AU</gtr:currLang><gtr:department>National Health and Medical Research Council</gtr:department><gtr:description>Project grant</gtr:description><gtr:end>2020-12-02</gtr:end><gtr:fundingOrg>Australian Government</gtr:fundingOrg><gtr:fundingRef>APP1127337</gtr:fundingRef><gtr:id>849476BB-7962-4D42-9053-BA62B946A796</gtr:id><gtr:outcomeId>58b3fdffd27c23.79892274</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>76254</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2015-02-02</gtr:end><gtr:fundingOrg>National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)</gtr:fundingOrg><gtr:fundingRef>G1100564</gtr:fundingRef><gtr:id>C77AA4F9-C568-4E2B-B2ED-FBED4CF252D9</gtr:id><gtr:outcomeId>JYihASRgkQT</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pump Priming Research Grant</gtr:description><gtr:end>2017-05-02</gtr:end><gtr:fundingOrg>British Lung Foundation (BLF)</gtr:fundingOrg><gtr:fundingRef>PPRG15-10</gtr:fundingRef><gtr:id>E8FBE99B-D54F-4068-ACFD-C861CB7803DB</gtr:id><gtr:outcomeId>56d4438a94a9a5.70007278</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>70802</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Proof of Concept Grant</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>UCL Business</gtr:fundingOrg><gtr:fundingRef>PoC-14-022</gtr:fundingRef><gtr:id>2B50112A-6537-4BCF-8D4F-8FBD7995883F</gtr:id><gtr:outcomeId>545a67f9a62bf6.96829271</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10771</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2014-08-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>094348</gtr:fundingRef><gtr:id>6A881FF5-33AB-4741-91CC-BD72033369EC</gtr:id><gtr:outcomeId>BtoFJ6hLEtr</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>95987</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>Raynaud's &amp; Scleroderma Association</gtr:fundingOrg><gtr:fundingRef>UC8</gtr:fundingRef><gtr:id>96C830B8-9FAA-4B2E-8EEF-C8BBE31B6FD6</gtr:id><gtr:outcomeId>56d441671009d4.88799860</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pump priming grant</gtr:description><gtr:end>2019-11-02</gtr:end><gtr:fundingOrg>British Lung Foundation (BLF)</gtr:fundingOrg><gtr:fundingRef>PPRG16-14</gtr:fundingRef><gtr:id>A3ACF1C4-BF92-4C74-B018-2235B43825D3</gtr:id><gtr:outcomeId>58b3ff20659f87.77431180</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Database of lung fibroblast genome-wide methylation and transcriptional profiles with and without DNMT treatment. Also included correlation between gene methylation and expression.</gtr:description><gtr:id>77F1311D-ED4D-4382-8BE4-59FD3D2B842A</gtr:id><gtr:impact>Data obtained from this database has enabled us to acquire further funding and contributed to published mechanistic research.</gtr:impact><gtr:outcomeId>56d44ce013fbc1.52167335</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Fibroblast epigenetic and transcriptional profiling database</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Data generated from genome-wide analysis of gene expression and DNA methylation from groups of control and fibrotic lung fibroblast cell lines with and without treatment with DNA methyltransferase inhibitors.</gtr:description><gtr:id>B5972A0A-7414-4971-95C0-07AAEEB6026B</gtr:id><gtr:impact>Ongoing analysis of this data is providing insights of targets for investigation in the regulation of PTGS2 expression as well as novel targets potentially involved in the pathogenesis of fibrotic lung disease. The investigation of novel targets is related to applications for further funding.</gtr:impact><gtr:outcomeId>ezm5TxxTabS</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Array data</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Isolation of DNA from groups of control and fibrotic lung fibroblast cell lines with and without treatment with DNA methyltransferase inhibitors.</gtr:description><gtr:id>50CE5323-7EB8-4AC4-B123-44521116DFFB</gtr:id><gtr:impact>This has allowed us to compare genome wide analyses of DNA methylation between control and fibrotic lung fibroblasts and to assess the effects of inhibiting DNA methylation.</gtr:impact><gtr:outcomeId>ZNfRAhF3odQ</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>DNA</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Isolation of new fibroblast cell lines from control and fibrotic lung.</gtr:description><gtr:id>EF4F1814-3291-44C3-8991-1FF451EC6298</gtr:id><gtr:impact>Increases our bank of fibroblast lines and increases our ability to share these resources and collaborate with other research groups.
Publication involving the use of this resource - PMID:
 22322297</gtr:impact><gtr:outcomeId>DgfKZrbZuH2</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Fibroblasts</gtr:title><gtr:type>Cell line</gtr:type><gtr:url>http://europepmc.org/abstract/MED/22322297</gtr:url><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Isolation of RNA from groups of control and fibrotic lung fibroblast cell lines with and without treatment with DNA methyltransferase inhibitors.</gtr:description><gtr:id>334D2B31-7613-460D-82C5-25B73174F264</gtr:id><gtr:impact>This has allowed us to compare genome wide analyses of gene expression between control and fibrotic lung fibroblasts and to assess the effects of inhibiting DNA methylation.</gtr:impact><gtr:outcomeId>avJvziwnG6o</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>RNA</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>AB5D1E4E-EF78-4396-BCCF-1AB49E1D2C51</gtr:id><gtr:title>Inhibition of neointimal hyperplasia in a rabbit vein graft model following non-viral transfection with human iNOS cDNA.</gtr:title><gtr:parentPublicationTitle>Gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72defccaf5d85c63dc727ba821f85243"><gtr:id>72defccaf5d85c63dc727ba821f85243</gtr:id><gtr:otherNames>Meng QH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0969-7128</gtr:issn><gtr:outcomeId>pm_14345_25_23636244</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE034A7A-366B-4A14-B3BA-4E59AC9CA866</gtr:id><gtr:title>Nebulisation of receptor-targeted nanocomplexes for gene delivery to the airway epithelium.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/710605d709dfc63e170a20fef8af8470"><gtr:id>710605d709dfc63e170a20fef8af8470</gtr:id><gtr:otherNames>Manunta MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14345_25_22046351</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4336C7BC-07BA-4F20-8887-7FEA56C09B3A</gtr:id><gtr:title>STAT3-mediated signaling dysregulates lung fibroblast-myofibroblast activation and differentiation in UIP/IPF.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/61bce0326222e621619cde3d583aefb0"><gtr:id>61bce0326222e621619cde3d583aefb0</gtr:id><gtr:otherNames>Pechkovsky DV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn><gtr:outcomeId>pm_14345_25_22322297</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C771429-6BF0-4A84-AFCB-AF7990A6561B</gtr:id><gtr:title>Models and approaches to understand the role of airway remodelling in disease.</gtr:title><gtr:parentPublicationTitle>Pulmonary pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2665bb935cdd7c37da7b53005be5d719"><gtr:id>2665bb935cdd7c37da7b53005be5d719</gtr:id><gtr:otherNames>McAnulty RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1094-5539</gtr:issn><gtr:outcomeId>pm_14345_25_21824523</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6AB0E17E-F2B3-4768-90E1-2327D1EFDFBF</gtr:id><gtr:title>Epigenetic regulation of cyclooxygenase-2 by methylation of c8orf4 in pulmonary fibrosis.</gtr:title><gtr:parentPublicationTitle>Clinical science (London, England : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfe2ae4da1c3131d5dc1dfb2fc5aafec"><gtr:id>cfe2ae4da1c3131d5dc1dfb2fc5aafec</gtr:id><gtr:otherNames>Evans IC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0143-5221</gtr:issn><gtr:outcomeId>56d43d511426e3.12395088</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC4C7573-CB99-4578-A43F-4BDC726CA78A</gtr:id><gtr:title>Hypomethylation of the TNXB gene contributes to increased expression and deposition of tenascin X in idiopathic pulmonary fibrosis</gtr:title><gtr:parentPublicationTitle>INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/040648f22891a7fd4273923a9691fd3e"><gtr:id>040648f22891a7fd4273923a9691fd3e</gtr:id><gtr:otherNames>Garner I. M.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0959-9673</gtr:issn><gtr:outcomeId>cEtys4wSu4G</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9FBC9E2F-A69A-475F-8175-15BB983AE719</gtr:id><gtr:title>NIK and IKKbeta interdependence in NF-kappaB signalling--flux analysis of regulation through metabolites.</gtr:title><gtr:parentPublicationTitle>Bio Systems</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/455a3c8e10397bb8bf6a55dafcdbc831"><gtr:id>455a3c8e10397bb8bf6a55dafcdbc831</gtr:id><gtr:otherNames>Kim HB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0303-2647</gtr:issn><gtr:outcomeId>pm_14345_15_19909783</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4150A8C-1A8B-4586-A0D0-421E014AE531</gtr:id><gtr:title>Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis.</gtr:title><gtr:parentPublicationTitle>EMBO molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/022bd8bddc6bd4a3533e3caa62feca0a"><gtr:id>022bd8bddc6bd4a3533e3caa62feca0a</gtr:id><gtr:otherNames>O'Donoghue RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1757-4676</gtr:issn><gtr:outcomeId>pm_14345_25_22684844</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4A9129B-CE5E-4A86-A395-6159937CDDBE</gtr:id><gtr:title>Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8264f3e245676159199c7659b0ef86cb"><gtr:id>8264f3e245676159199c7659b0ef86cb</gtr:id><gtr:otherNames>Mercer PF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>58b40228c6f499.85458237</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F73FAF62-2BEA-411F-AC76-FD266C41EA0A</gtr:id><gtr:title>Airway deposition of nebulized gene delivery nanocomplexes monitored by radioimaging agents.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory cell and molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/710605d709dfc63e170a20fef8af8470"><gtr:id>710605d709dfc63e170a20fef8af8470</gtr:id><gtr:otherNames>Manunta MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1044-1549</gtr:issn><gtr:outcomeId>pm_14345_25_23614789</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AD3992A-7DE5-4590-90C6-F7F19B3F36F4</gtr:id><gtr:title>Genome-wide analysis identifies multiple genes with altered methylation and expression in IPF and SSc lung fibroblasts</gtr:title><gtr:parentPublicationTitle>INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/040648f22891a7fd4273923a9691fd3e"><gtr:id>040648f22891a7fd4273923a9691fd3e</gtr:id><gtr:otherNames>Garner I. M.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0959-9673</gtr:issn><gtr:outcomeId>cLqU6gYZnaF</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1000440</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>